Drugs / T-1201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04866641 | Jun 2021 → Jun 2026 overdue | neoplasm | Taivex Therapeutics Corporation | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-08 | Taivex Therapeutics Corporation | T-1201 Phase I study design present at 2025 ASCO taivex.com ↗ |
| 2024-11-28 | Taivex Therapeutics Corporation | Taivex’s ‘s T-1101 and T-1201 Invited to Present Study Progress at KSMO 2024 Annual Meeting taivex.com ↗ |
| 2024-06-12 | Taivex Therapeutics Corporation | Groundbreaking Cancer Treatments T-1201 and T-1301 to be Presented at WCC-2024 taivex.com ↗ |
| 2017-07-15 | Taivex Therapeutics Corporation | T-1201 get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award taivex.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-1201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04866641 ↗ |
| Route | Intravenous | “formulated for intravenous administration.” NCT04866641 ↗ |